- Home
- QUAD vs ELDN Comparison
QUAD vs ELDN Comparison
Compare QUAD & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUAD
- ELDN
- Stock Information
- Founded
- QUAD 1971
- ELDN 2004
- Country
- QUAD United States
- ELDN United States
- Employees
- QUAD N/A
- ELDN N/A
- Industry
- QUAD Publishing
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- QUAD Consumer Discretionary
- ELDN Health Care
- Exchange
- QUAD Nasdaq
- ELDN Nasdaq
- Market Cap
- QUAD 287.7M
- ELDN 232.4M
- IPO Year
- QUAD 2010
- ELDN N/A
- Fundamental
- Price
- QUAD $5.53
- ELDN $3.22
- Analyst Decision
- QUAD Strong Buy
- ELDN Strong Buy
- Analyst Count
- QUAD 2
- ELDN 1
- Target Price
- QUAD $10.15
- ELDN $16.00
- AVG Volume (30 Days)
- QUAD 223.6K
- ELDN 261.7K
- Earning Date
- QUAD 04-29-2025
- ELDN 05-08-2025
- Dividend Yield
- QUAD 4.09%
- ELDN N/A
- EPS Growth
- QUAD N/A
- ELDN N/A
- EPS
- QUAD N/A
- ELDN N/A
- Revenue
- QUAD $2,672,200,000.00
- ELDN N/A
- Revenue This Year
- QUAD N/A
- ELDN N/A
- Revenue Next Year
- QUAD N/A
- ELDN N/A
- P/E Ratio
- QUAD N/A
- ELDN N/A
- Revenue Growth
- QUAD N/A
- ELDN N/A
- 52 Week Low
- QUAD $4.06
- ELDN $1.52
- 52 Week High
- QUAD $9.13
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- QUAD 42.51
- ELDN 30.78
- Support Level
- QUAD $5.29
- ELDN $3.22
- Resistance Level
- QUAD $5.58
- ELDN $3.45
- Average True Range (ATR)
- QUAD 0.16
- ELDN 0.19
- MACD
- QUAD 0.04
- ELDN -0.01
- Stochastic Oscillator
- QUAD 52.17
- ELDN 7.01
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.